BRYREL Drug Patent Profile
Which patents cover Bryrel, and when can generic versions of Bryrel launch?
Bryrel is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in BRYREL is piperazine citrate. There is one drug master file entry for this compound. Additional details are available on the piperazine citrate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BRYREL?
- What are the global sales for BRYREL?
- What is Average Wholesale Price for BRYREL?
Summary for BRYREL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Patent Applications: | 320 |
| DailyMed Link: | BRYREL at DailyMed |
US Patents and Regulatory Information for BRYREL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | BRYREL | piperazine citrate | SYRUP;ORAL | 017796-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
